Crescendo 2 is an award-winning FDA-registered medical device designed to assist women suffering from sexual health issues like arousal disorder and genito-pelvic pain/penetration disorder. Crescendo 2 aims to elevate sexual health and pleasure while mitigating pain barriers from circumstances or age, such as menopause and childbirth. The Bluetooth, bendable vibrating device is the world’s first of its kind that offers an affordable, accessible solution to sexual dysfunction without the side effects of medication. Crescendo 2’s uniqueness comes from its revolutionary adaptable design. The device can be bent into different shapes and work with various body shapes and sizes. In addition to being an ultra-flexible, bendable electronic, it retains its shape under pressure. With superior bendability, the device can deliver localized vibrations and stimulation to the exact areas that need pain relief, both internally and externally. The patent-pending technology of Crescendo 2’s six strategically placed motors and sixteen intensity settings deliver multi-targeted vibrations resulting in increased blood flow and prolonged, personalized pleasure. For those seeking to use the device for purely recreational purposes, Crescendo 2 is a gender-agnostic device that can be adapted for multiple purposes. Crescendo 2 comes with a free smartphone app that allows remote connectivity and the ability to program the speed, intensity, and pattern of each individual motor. Crescendo 2 also comes with a free smartphone app that enables the user to set the vibration pattern and intensity that is most suitable for them. Crescendo, was trialed in a medical study and was found to improve Genito-Pelvic Pain & Penetration Disorder by an unprecedented 480%. The medical study focusing on Crescendo’s therapy system improving genito-pelvic pain/penetration disorder was conducted by Dr. Jesús E. Rodríguez of the Murcian Institute of Sexology and The Comprehensive Center for Gynecology and Obstetrics. The findings were presented at SMSNA’s 22nd Scientific Meeting, and the study was published in the Journal of Sexual Medicine.